Related Experiment Video

Updated: Mar 31, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Decrease of small dense LDL and lipoprotein-associated phospholipase A2 due to human growth hormone treatment in

Andreas Krebs, Thomas Kratzin, Jürgen Doerfer

    Journal of Pediatric Endocrinology & Metabolism : JPEM
    |October 27, 2015
    PubMed

    Insights

    Growth hormone (GH) treatment reduced cardiovascular risk factors in children with growth hormone deficiency (GHD) or born small for gestational age (SGA). GH therapy improved lipid profiles and decreased inflammation markers, suggesting long-term cardiovascular benefits.

    Area of Science:

    • Pediatric Endocrinology
    • Cardiovascular Risk Assessment
    • Biochemistry

    Background:

    • Growth hormone deficiency (GHD) and small for gestational age (SGA) are linked to increased cardiovascular risks.
    • Investigating the antiatherogenic potential of growth hormone (GH) is crucial for managing these risks.

    Purpose of the Study:

    • To evaluate the antiatherogenic effects of GH treatment in children with GHD or born SGA.
    • To assess changes in lipoprotein subfractions, Lp-PLA2, and hsCRP levels following GH therapy.

    Main Methods:

    • 51 children (33 SGA, 18 GHD) received GH treatment for 52 weeks.
    • Measurements included LDL and HDL subfractions, Lp-PLA2, and hsCRP at baseline and follow-up.
    • Analysis compared pre- and post-treatment values and correlated specific markers.

    Main Results:

    • GH treatment led to significant reductions in LDL cholesterol, small-dense LDL cholesterol (sdLDL-C), Lp-PLA2, and hsCRP.
    • An increase in HDL2a cholesterol was observed.
    • SGA children showed significant correlations between Lp-PLA2, LDL-C, and sdLDL-C, with notable improvements in these markers.

    Conclusions:

    • GH therapy offers potential cardiovascular benefits for children with GHD or born SGA.
    • GH treatment may reduce long-term cardiovascular risks by improving lipid profiles and reducing inflammation.
    Abstract

    More Related Videos

    Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays11:17

    Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

    Published on: January 7, 2016

    17.2K
    Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein07:29

    Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

    Published on: October 12, 2017

    9.9K

    Related Concept Videos

    Nature and Nurture01:10

    Nature and Nurture

    Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
    22.8K
    Signs of Puberty01:27

    Signs of Puberty

    Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
    2.0K
    Insulin: Dosing Regimen and Adverse Effects01:16

    Insulin: Dosing Regimen and Adverse Effects

    Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
    The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
    1.2K
    Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

    Pharmacokinetics in Pediatric Patients: Drug Distribution

    Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
    464
    Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

    Blood Studies for Cardiovascular System III: Serum Lipid Profile

    Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
    Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
    Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
    827
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
    332